CERT - Certara, Inc. Stock Price, Fair Value and News

15.70USD+0.15 (+0.96%)Market Closed

Market Summary

USD15.70+0.15

Market Closed

0.96%

CERT Stock Price

View Fullscreen

CERT RSI Chart

CERT Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-40.74

Price/Sales (Trailing)

6.93

EV/EBITDA

-66.98

Price/Free Cashflow

33.34

CERT Price/Sales (Trailing)

CERT Profitability

Operating Margin

60.90%

EBT Margin

-17.48%

Return on Equity

-5.82%

Return on Assets

-3.98%

Free Cashflow Yield

CERT Fundamentals

CERT Revenue

Revenue (TTM)

360.7M

Rev. Growth (Yr)

7.04%

Rev. Growth (Qtr)

9.82%

CERT Earnings

Earnings (TTM)

-61.4M

Earnings Growth (Yr)

-444.85%

Earnings Growth (Qtr)

62.4%

Breaking Down CERT Revenue

Last 7 days

-2.9%

Last 30 days

16.4%

Last 90 days

-6.2%

Trailing 12 Months

-19.3%

How does CERT drawdown profile look like?

CERT Financial Health

Current Ratio

3.26

Debt/Equity

0.27

Debt/Cashflow

0.27

CERT Investor Care

Shares Dilution (1Y)

0.63%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	360.7M	0	0	0
2023	344.4M	352.1M	353.0M	354.3M
2022	300.9M	313.6M	324.4M	335.6M
2021	252.8M	261.8M	275.4M	286.1M
2020	217.3M	226.0M	234.8M	243.5M
2019	0	0	0	208.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Certara, Inc.

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CEO	Dr. William F. Feehery Ph.D.
WEBSITE	certara.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1150

Certara, Inc. Frequently Asked Questions

What is the ticker symbol for Certara, Inc.? What does CERT stand for in stocks?

CERT is the stock ticker symbol of Certara, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Certara, Inc. (CERT)?

As of Thu Jul 25 2024, market cap of Certara, Inc. is 2.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERT stock?

You can check CERT's fair value in chart for subscribers.

Is Certara, Inc. a good stock to buy?

The fair value guage provides a quick view whether CERT is over valued or under valued. Whether Certara, Inc. is cheap or expensive depends on the assumptions which impact Certara, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERT.

What is Certara, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, CERT's PE ratio (Price to Earnings) is -40.74 and Price to Sales (PS) ratio is 6.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERT PE ratio will change depending on the future growth rate expectations of investors.